Retatrutide

Appetite, energy expenditure, glycemic control, and metabolic disease research

Triple GLP-1/GIP/glucagon receptor agonist peptide

Investigational; not FDA-approved

Overview

Retatrutide (LY3437943) is an investigational peptide designed to activate three metabolic hormone receptors: GLP-1, GIP, and glucagon. The research rationale is to combine incretin-related effects on appetite and glucose regulation with glucagon-receptor effects on energy expenditure and lipid metabolism. Phase 2 human studies have reported substantial changes in body weight and metabolic markers, and larger clinical-development programs have continued to evaluate obesity and metabolic disease. Retatrutide remains investigational and should not be described as an approved weight-loss medication.

How it works

checkCreated with Sketch.

GLP-1 receptor activity: Influences appetite, insulin secretion, glucagon regulation, and gastrointestinal signaling.

checkCreated with Sketch.

GIP receptor activity: Adds a second incretin pathway involved in insulinotropic and metabolic signaling.

checkCreated with Sketch.

Glucagon receptor activity: Investigated for effects on energy expenditure, hepatic lipid metabolism, and fuel utilization.

Research areas

checkCreated with Sketch.

Obesity research

checkCreated with Sketch.

Type 2 diabetes research

checkCreated with Sketch.

Liver-fat / metabolic liver research

checkCreated with Sketch.

Cardiometabolic endpoints

Research / study context

one

Phase 2 obesity trial: Randomized human research evaluated multiple dose groups over extended treatment and measured body weight, metabolic markers, and adverse events.

two

Metabolic clinical studies: Additional trials have examined glycemic control and related metabolic outcomes.

Key research findings

checkCreated with Sketch.

Phase 2 studies demonstrate strong pharmacologic effects on body-weight endpoints.

checkCreated with Sketch.

Gastrointestinal adverse events are common in incretin-based clinical research.

checkCreated with Sketch.

Long-term benefit-risk and regulatory status remain under investigation.

Scientific reference starter set

one

Peptide Education Hub: Retatrutide profile

two

PubMed search: retatrutide triple hormone receptor agonist obesity phase 2

three

ClinicalTrials.gov search: retatrutide

Research material

View available specifications and batch documentation in the Apex catalog.

Important

For research use only. Not for human consumption. This profile is educational and does not provide treatment or personal-use instructions.